Report of Independent Registered Public Accounting Firm
To the Board of Directors of iShares, Inc. and Shareholders of iShares International High Yield Bond ETF,
iShares J.P. Morgan EM Corporate Bond ETF, iShares J.P. Morgan EM High Yield Bond ETF, iShares J.P.
Morgan EM Local Currency Bond ETF and iShares US & Intl High Yield Corp Bond ETF
In planning and performing our audits of the financial statements of the funds listed in Appendix A,
(hereafter referred to as the “Funds”) as of and for the year ended October 31, 2021, in accordance with the
standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered
the Funds’ internal control over financial reporting, including controls over safeguarding securities, as a
basis for designing our auditing procedures for the purpose of expressing our opinion on the financial
statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an
opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we do not
express an opinion on the effectiveness of the Funds’ internal control over financial reporting.
The management of the Funds is responsible for establishing and maintaining effective internal control
over financial reporting. In fulfilling this responsibility, estimates and judgments by management are
required to assess the expected benefits and related costs of controls. A company’s internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles. A company’s internal control over financial reporting includes
those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and
directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of a company’s assets that could have a material effect on
the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk
that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
A deficiency in internal control over financial reporting exists when the design or operation of a control
does not allow management or employees, in the normal course of performing their assigned functions, to
prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of the company’s annual or interim financial statements will not be prevented or
detected on a timely basis.
Our consideration of the Funds’ internal control over financial reporting was for the limited purpose
described in the first paragraph and would not necessarily disclose all deficiencies in internal control over
financial reporting that might be material weaknesses under standards established by the PCAOB.
However, we noted no deficiencies in the Funds’ internal control over financial reporting and its
operation, including controls over safeguarding securities, that we consider to be material weaknesses as
defined above as of October 31, 2021.
This report is intended solely for the information and use of the Board of Directors of iShares, Inc. and the
Securities and Exchange Commission and is not intended to be and should not be used by anyone other
than these specified parties.
/s/PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
December 21, 2021
Appendix A
iShares, Inc.
Limited Access